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Effect of Epigenetic Inhibitors on Lung Fibroblast Phenotype Change in Idiopathic Pulmonary Fibrosis 
 
Alice Pasini1, Oliver J Brand1, Gisli Jenkins1, Alan J Knox1 and Linhua Pang1 
1Division of Respiratory Medicine - University of Nottingham, Nottingham, UK. 
 
Introduction and objectives Idiopathic Pulmonary Fibrosis (IFP) is a fatal interstitial lung disease with 
unknown aetiology. Lung myofibroblasts (activated fibrobalsts) are the major effector cells in the 
pathogenesis of IPF. Transforming growth factor-β (TGF-β1) is a potent activator of fibroblasts. Lack of 
effective treatment options necessitates novel therapeutic approaches. Epigenetic drugs, by inhibiting 
chromatin modifying enzymes involved in gene expression control, represent promising agents capable of 
modulating the cellular phenotype.  
We previously demonstrated that the cyclooxygenase-2 (COX-2) gene is epigenetically silenced in lung 
fibroblasts from IPF patients (F-IPF)[1] and epigenetic inhibitors and restore COX-2 expression. However, 
whether epigenetic inhibitors can alter fibroblast phenotype remains unknown. This study aimed to 
investigate the effect of four different epigenetic enzyme inhibitors on fibroblast phenotype change in IPF.  
Methods F-IPF and fibroblasts from non-fibrotic lung (F-NL) treated with TGF-β1 were cultured to test the 
effects of the epigenetic inhibitors BIX01294 (BIX, G9a histone methyltransferase inhibitor), 3-
deazaneplanocin A (DZNep, EZH2 histone methyltransferase inhibitor), SAHA (histone deacetylases 
inhibitor) and Decitabine (DAC, DNA demethylating agent), in comparison with the COX-2 products 
prostaglandin E2 (PGE2). The expression of COX-2 and myofibroblast markers collagen 1 (COL1) and α-
smooth muscle actin (α-SMA) was assessed. The COX-2 DNA promoter methylation level was analysed by 
bisulfite sequencing.  
Results TGF-β1 induced a myofibroblast phenotype in F-NL characterised by COL1 and α-SMA upregulation 
and COX-2 downregulation, similar to F-IPF. PGE2 and SAHA were able to maintain/restore COX-2 
expression in TGF-β1-induced myofibroblasts and F-IPF. DAC demonstrated similar effect in TGF-β1 treated 
F-NL only.  SAHA also reduced COL1 and α-SMA expression. But DZNep and BIX showed no effect. No 
differences in the COX-2 promoter methylation was detected between F-NL and F-IPF. 
Conclusions Among the epigenetic inhibitors tested, SAHA shows a promising antifibrotic effect by 
inhibiting fibroblast activation and the underlying molecular mechanisms are currently under investigation. 
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